April 2010 in “Cancer Research” Basal cell carcinomas may use IDO to protect themselves from the immune system.
1 citations
,
March 2023 in “International Wound Journal” CCN1 may aid wound healing, but more research with larger samples is needed.
561 citations
,
April 2003 in “Journal of Investigative Dermatology” CD34 is a marker for isolating stem-like cells in mouse hair follicles.
20 citations
,
May 2016 in “Journal of Cutaneous Pathology” Using CD123 to detect certain immune cells helps diagnose a type of hair loss condition.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
February 2020 in “Oncology Times” Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
17 citations
,
January 2010 in “PubMed” CD10 helps distinguish between basal cell carcinoma and benign hair follicle tumors.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” miR-486 may help prevent hair loss in alopecia areata.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
7 citations
,
May 1993 in “Journal of the European Academy of Dermatology and Venereology” Cell adhesion molecules are important in the development of certain skin diseases.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
70 citations
,
December 2008 in “Cancer Research” CXCR2 in skin cells promotes tumor growth.
April 2018 in “Journal of Investigative Dermatology” CREB, a protein that can promote cancer traits, is controlled by β-catenin in skin cancer cells.
January 2004 in “Kölner Universitäts PublikationsServer (Universität zu Köln)” Collagen XVII and CD151 affect cell movement, with CD151 inhibiting migration when bound to integrins.
11 citations
,
March 2014 in “Journal of Investigative Dermatology” Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.
1 citations
,
July 2025 in “Scientific Reports” CD133+ cells are crucial for hair growth.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
1 citations
,
November 2024 in “Cureus” Recognizing RSCC is crucial due to its aggressive nature and high risk of poor outcomes.
19 citations
,
August 2019 in “Journal of Cellular Biochemistry” ADSCs help protect skin from UV damage and aging.
3 citations
,
October 2020 in “Journal of Investigative Dermatology” Removing β-catenin in certain stem cells causes hair whitening and pigmentation issues.
March 2025 in “OncoTargets and Therapy” A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.
August 1994 in “American Journal of Veterinary Research” Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.
24 citations
,
January 2019 in “Theranostics” Loss of Pten in certain hair follicle stem cells increases skin cancer risk.
May 2026 in “Chemical Engineering Journal”
April 2017 in “Journal of Dermatological Science” B cells can both help and hinder the body's defense against melanoma.
5 citations
,
May 2023 in “Frontiers in Cell and Developmental Biology” Integrin α6 helps identify different neural crest cell types in the skin.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.